Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Dainippon's Phase III Schizophrenia Trial Shows Lurasidone Advantage Over Placebo, But Not Against Zyprexa

This article was originally published in PharmAsia News

Executive Summary

Dainippon Sumitoma Pharma Co. does have enough positive pivotal trials for its planned 2010 NDA filing for the atypical antipsychotic lurasidone, but the newly released data from one of those trials reveal a discrepancy in the efficacy results that could be a hurdle at U.S. FDA

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts